Treatment for Uncomplasma genitalium Infection
For uncomplicated Mycoplasma genitalium infection, use resistance-guided therapy: azithromycin 500 mg on day 1, then 250 mg daily on days 2-5 for macrolide-susceptible infections, or moxifloxacin 400 mg daily for 7 days for macrolide-resistant infections. 1
Current Treatment Landscape
The treatment of M. genitalium has fundamentally changed due to widespread antimicrobial resistance. Macrolide resistance now affects 30-50% of infections in Europe and the Americas, and exceeds 60% in Asia 2. In the UK, macrolide resistance reaches 55.5% 3. This makes resistance testing essential before selecting therapy.
Recommended Treatment Algorithm
First-Line Treatment (Macrolide-Susceptible or Unknown Resistance)
- Azithromycin extended regimen: 500 mg orally on day 1, then 250 mg daily on days 2-5 1
Second-Line Treatment (Macrolide-Resistant Infection)
- Moxifloxacin: 400 mg orally once daily for 7 days 1
- Use when macrolide resistance mutations are detected
- Fluoroquinolone resistance is emerging (20.6% in some UK regions 3), making this less reliable over time
Doxycycline Lead-In Strategy
While not universally required, doxycycline 100 mg twice daily for 7 days before azithromycin or moxifloxacin may reduce organism load and decrease selection of macrolide resistance 5, 1. However, doxycycline alone has only 30-40% cure rates 1.
Critical Considerations
Resistance Testing is Essential
Macrolide resistance testing must be performed whenever possible before initiating treatment 1. The 2021 European guideline emphasizes this shift from empiric therapy to resistance-guided treatment. Without testing, you risk treatment failure in over half of patients in high-resistance areas.
When Resistance Testing is Unavailable
If macrolide resistance testing is not accessible and the patient is symptomatic:
- Consider moxifloxacin 400 mg daily for 7 days as first-line to avoid azithromycin failure
- Alternatively, use the extended azithromycin regimen and monitor closely for treatment failure
Treatment Failures and Third-Line Options
For persistent infection after both azithromycin and moxifloxacin failure 1:
- Doxycycline or minocycline 100 mg twice daily for 14 days (40-70% cure rate)
- Pristinamycin 1g four times daily for 10 days (~75% cure rate, where available)
Important Pitfalls to Avoid
Do not use the outdated single-dose azithromycin 1g regimen 4 as standard therapy—this was recommended in 2010 before widespread resistance was recognized
Do not screen or treat asymptomatic patients 5—testing should be symptom-driven only
Ensure 7-day sexual abstinence after completing treatment and until partners are treated 4
Do not perform routine test-of-cure in asymptomatic patients 5, though this may be considered in treatment failures
The Resistance Crisis
The evidence consistently shows that M. genitalium treatment is complicated by rapid antimicrobial resistance expansion 6. Dual macrolide-fluoroquinolone resistance is emerging, particularly in Asia 2, creating scenarios where standard therapies fail. This underscores why resistance-guided therapy is now the standard of care 1, representing a major shift from the 2010 CDC guidelines 4 which recommended empiric azithromycin.
The most recent and authoritative guidance comes from the 2021 European guideline 1, which explicitly narrowed testing and treatment indications to symptomatic patients due to increasing resistance and the need to preserve effective antimicrobials.